@article{4f5437fc5ba446fca4e2d681b20b67e9,
title = "Preliminary reliability and validity of a new time-sensitive ADHD symptom scale in adolescents with ADHD",
abstract = "Objectives: To validate the Time-Sensitive ADHD Symptom Scale (TASS) in the assessment of symptom change during the day in adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods: A total of 40 participants with ADHD aged 13 to 17 years completed 1 or 2 visits, 1 to 9 weeks apart. The TASS and the ADHD Rating Scale-IV (ADHD-RS-IV) were completed twice at each visit: at the time of the clinic visit (in-clinic assessment) and 2 to 6 hours afterwards (evening assessment). Results: Internal consistency of the TASS was high, with Cronbach's alpha coefficients of 0.91 (in-clinic) and 0.90 (evening) for visit 1, and 0.88 (in-clinic) and 0.86 (evening) for visit 2. Pearson's correlation coefficients between the TASS and ADHD-RS-IV were significant at both visits (P < 0.0001). Stability analyses of the TASS found no significant effect between ratings performed at different visits (P = 0.936), but there was a significant effect of the assessment time within visits (P < 0.0001). There was not a significant visit by assessment time interaction (P = 0.924). Conclusions: The TASS showed high internal consistency and high concurrent validity with the ADHD-RS-IV. Results of this preliminary study indicate that the TASS is a valid and reliable self-report scale for adolescents with ADHD.",
keywords = "ADHD, Adolescents, Classifi cation, Psychometrics, Questionnaires",
author = "Adler, \{Lenard A.\} and Shaw, \{David M.\} and Spencer, \{Thomas J.\} and Newcorn, \{Jeffrey H.\} and Sitt, \{David J.\} and Minerly, \{Ana Christina E.\} and Davidow, \{Jennifer V.\} and Faraone, \{Stephen V.\}",
note = "Funding Information: Lenard A. Adler, MD has received grant/research support from the following sources: Bristol-Myers Squibb, Chelsea Therapeutics, Eli Lilly \& Company, National Institute of Drug Abuse, Ortho McNeil/Janssen/Johnson \& Johnson, Pfizer Inc, and Shire Laboratories, Inc. Dr. Adler has been a speaker or on the speakers{\textquoteright} bureaus for the following companies: Ortho McNeil/Janssen/Johnson \& Johnson and Shire Laboratories, Inc. Dr. Adler has served on the advisory board for Eli Lilly \& Company, i3 Research, Major League Baseball, Mindsite, Organon, Ortho McNeil/ Janssen/Johnson \& Johnson, and Shire Laboratories, Inc. Dr. Adler has consulted with Epi-Q, INC Research, Major League Baseball Players Association, and United Biosource Corporation. Dr. Adler has received royalty payments (as inventor) from the NYU School of Medicine for license Funding Information: This study was funded in part by an investigator-initiated research grant from Shire Development, Inc., Wayne, PA. In compliance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, established by the International Committee of Medical Journal Editors, Shire Development, Inc. did not impose any impediment, directly or indirectly, on the publication of the study{\textquoteright}s results. Employees of Shire Development, Inc. were not involved in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.",
year = "2011",
month = sep,
doi = "10.3810/pgm.2011.09.2455",
language = "English",
volume = "123",
pages = "7--13",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Taylor and Francis Ltd.",
number = "5",
}